ImmunoGen, Inc.(IMGN): For the most recent quarter end, ImmunoGen, Inc. reported Annual Earnings of $-0.39. Based on the filings, last years Annual Earnings was, $-1.65. For the most recent quarter end, IMGN reported a surprise Earnings per Share of -2.63% . The consensus estimate for current quarter is $-0.39 and for the current fiscal year, the estimate is $-1.64. For the Next fiscal year, the estimate is $-1.54 based on the consensus.
ImmunoGen, Inc. has received $-0.39 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.42 while the top line estimate is $-0.34 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -4.32%. ImmunoGen, Inc. results fell short with a surprise EPS of -2.63% or $-0.01. The Actual EPS was $-0.39 compared to the Estimated EPS of $-0.38 during its most recent quarterly earnings.
ImmunoGen Last issued its quarterly earnings results on Feb 17, 2017. The company reported $-0.39 EPS for the quarter. Analyst had a consensus estimate of $-0.39. The company had revenue of $13.85 million for the quarter, compared to analysts expectations of $16.28 million. The companys revenue was down -23.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.38 EPS.
Company has reported several Insider transactions to the SEC, on Dec 15, 2016, Mark Alan Goldberg (director) purchased 20,000 shares at 1.80 per share price.On Nov 9, 2016, Mark J Enyedy (CEO) purchased 25,000 shares at 1.83 per share price.On Nov 3, 2016, John Lambert (Executive Vice President) purchased 2,775 shares at 1.68 per share price.
Wednesdays trading session turned out to be a no-profit no-loss event for ImmunoGen, Inc. (NASDAQ:IMGN). The opening trade occurred at $2.47 and the highest and the lowest points of the day were $2.51 and $2.45 respectively. The final trade was registered at $2.47 and the volume by the end of the day had touched 861,718 shares. The 52-week high of the stock is $9.78 and the 52-week low is $1.51. According to the current valuation, the market cap of the company is $216 million and the total number of shares available in public circulation is 87,301,341.
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The companys product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.